You are here: Industry Insights > Merck KGaA

News List

BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology B3Cnewswire
February 07, 2022
German independent research institute BioMed X announces today the extension of its collaboration with Merck KGaA, Darmstadt, Germany, in the research project RNA Splicing in Cancer (RSC).
Merck KGaA to Acquire Exelead for $780M contractpharma
January 06, 2022
Enhances the company's experience in producing lipids, one of the critical components for the formulation of mRNA therapeutics including Covid-19 vaccines.
Merck KGaA to design manufacturing process for first Nigerian vaccine plant through Innovative Biotech partnership CPhIonline
December 16, 2021
Merck will design the manufacturing process to help accelerate self-sufficient vaccine development and manufacturing in West Africa.
Merck KGaA, Darmstadt, Germany, Announces Change in IT Leadership firstwordpharma
August 26, 2021
Merck KGaA, Darmstadt, Germany, today announced that Dirk Toepfer, Group CIO and Head of Information Technology, has decided to leave the company effective August 31, to continue his career in consulting outside of Merck KGaA, Darmstadt, Germany.
Merck KGaA appoints Renee Connolly as Chief Diversity Equity & Inclusion Officer firstwordpharma
July 09, 2021
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that Renee Connolly has been appointed Chief Diversity Equity & Inclusion (DE&I) Officer, effective August 1.
BioMed X and Merck KGaA, Darmstadt, Germany Launch New Research Program in Oncology b3cnewswire
July 06, 2021
BioMed X, a leading independent research institute, announced today the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany.
Pharmaceutical QC market to value $9,700mn by 2027 europeanpharmaceuticalreview
July 02, 2021
Market research shows increasing pharmaceutical R&D investment and advances in quality control (QC) technologies will drive pharmaceutical QC market growth.
Indivumed Launches the nRavel AI Platform for Cancer Research and Drug Development firstwordpharma
June 03, 2021
Indivumed GmbH ("Indivumed") today announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.
Merck KGaA boosts lipid capacity to meet vaccine demand cphi-online
May 31, 2021
The company's new synthetic cholesterol product will help meet the demand for mRNA vaccines, including Pfizer-BioNTech Covid-19 Vaccine
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study prnasia
March 10, 2021
Genome and Company, a leading global microbiome anti-cancer drug development company, signed a second clinical trial collaboration and supply agreement (CTCSA) with Merck KGaA, Darmstadt, Germany and Pfizer Inc. with the aim of developing the world's ...

Previous page 1 2 3 4 Next page